Efficacy and Safety of a Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 3-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study.

被引：0
|
作者：
Kolodny, S. [1 ]
Khan, O. [2 ,3 ]
Rieckmann, P. [4 ]
Davis, M. D. [5 ]
Ashtamker, N. [6 ]
Steinerman, J. R. [5 ]
Zivadinov, R. [7 ]
Grinspan, A. [5 ]
机构：
[1] Teva Pharmaceut, Cleveland, OH USA
[2] Wayne State Univ, Sch Med, Sastry Fdn Adv Imaging Lab, Detroit, MI USA
[3] Wayne State Univ, Sch Med, Dept Neurol, Multiple Sclerosis Ctr, Detroit, MI 48201 USA
[4] Univ Erlangen Nurnberg, Bamberg Acad Hosp, Dept Neurol, Bamberg, Germany
[5] Teva Pharmaceut, Frazer, PA USA
[6] Teva Pharmaceut, Netanya, Israel
[7] SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurol, Buffalo, NY 14260 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-33
引用
收藏
页码：417 / 417
页数：1
相关论文
共 47 条
  • [1] Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the glatiramer acetate low-frequency administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Kolodny, S.
    Davis, M. D.
    Ashtamker, N.
    Steinerman, J. R.
    Zivadinov, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 119 - 120
  • [2] Efficacy and safety of a 3 times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
    Khan, O.
    Rieckmann, P.
    Boyko, A. N.
    Selmaj, K. W.
    Ashtamker, N.
    Davis, M. D.
    Kolodny, S.
    Zivadinov, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 711 - 711
  • [3] Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
    Khan, Omar
    Rieckmann, Peter
    Boyko, Alexey
    Selmaj, Krzysztof
    Ashtamker, Natalia
    Davis, Mat D.
    Kolodny, Scott
    Zivadinov, Robert
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) : 818 - 829
  • [4] Long-term efficacy, safety, and tolerability of three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 5-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study
    Alexander, Jessica
    Beygi, Hooman
    Feldman, Peter
    Ashtamker, Natalia
    [J]. NEUROLOGY, 2018, 90
  • [5] Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
    Rieckmann, Peter
    Zivadinov, Robert
    Boyko, Alexey
    Selmaj, Krzysztof
    Alexander, Jessica K.
    Kadosh, Shaul
    Rubinchick, Svetlana
    Bernstein-Hanlon, Emily
    Stark, Yafit
    Ashtamker, Natalia
    Davis, Mat D.
    Khan, Omar
    [J]. MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [6] Time Course of Glatiramer Acetate Efficacy in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in the Glatiramer Acetate Low-Frequency Administration (GALA) Study
    Kolodny, S.
    Davis, M. D.
    Ashtamker, N.
    Steinerman, J. R.
    Knappertz, V.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 333 - 334
  • [7] Long-term efficacy including clinical NEDA and safety of three-times-weekly dosing regimen of glatiramer acetate: 7-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study
    Rieckmann, P.
    Alexander, J.
    Kadosh, S.
    Rubinchick, S.
    Stark, Y.
    Zivadinov, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 325 - 326
  • [8] Magnetic Resonance Imaging (MRI) Indicators of Brain Tissue Loss: 3-Year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-Label Extension Study in Relapsing-Remitting Multiple Sclerosis
    Kolodny, S.
    Zivadinov, R.
    Dwyer, M. G.
    Bergsland, N. P.
    Ramasamy, D. P.
    Carl, E. M.
    Davis, M. D.
    Khan, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 334 - 334
  • [9] Long-term follow-up of three-times-weekly glatiramer acetate: 7-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study
    Rieckmann, P.
    Alexander, J.
    Kadosh, S.
    Rubinchick, S.
    Stark, Y.
    Zivadinov, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 194 - 194
  • [10] Predictors of Disability in Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate Low-frequency Administration (GALA) Study
    Alexander, Jessica
    Daudt, Donald R.
    Davis, Mat D.
    Ashtamker, Natalia
    Kolodny, Scott
    [J]. NEUROLOGY, 2017, 88
12345